[go: up one dir, main page]

WO2009057294A1 - 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法 - Google Patents

肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法 Download PDF

Info

Publication number
WO2009057294A1
WO2009057294A1 PCT/JP2008/003082 JP2008003082W WO2009057294A1 WO 2009057294 A1 WO2009057294 A1 WO 2009057294A1 JP 2008003082 W JP2008003082 W JP 2008003082W WO 2009057294 A1 WO2009057294 A1 WO 2009057294A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver cancer
gene
risk
acquiring
detect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003082
Other languages
English (en)
French (fr)
Inventor
Takeaki Ishizawa
Norihiro Kokudo
Hirohide Yoshikawa
Yuko Shikauchi
Yaeko Murase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
University of Tokyo NUC
Original Assignee
Japanese Foundation for Cancer Research
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research, University of Tokyo NUC filed Critical Japanese Foundation for Cancer Research
Priority to EP08845421.0A priority Critical patent/EP2210942B1/en
Priority to US12/740,687 priority patent/US20110218121A1/en
Priority to CN200880114256A priority patent/CN101855348A/zh
Priority to ES08845421.0T priority patent/ES2510842T3/es
Publication of WO2009057294A1 publication Critical patent/WO2009057294A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

【課題】患者から採取した血液を用いて、患者に負担の少ない、肝癌の早期発見、肝癌のリスクを検出し判定する方法、及びその検出に利用できる遺伝子マーカー、プローブ、プライマー並びに試薬キットの提供。 【解決手段】　下記のメチル化された遺伝子又は遺伝子領域の全てを検出できるポリヌクレオチドからなる肝臓癌の罹患診断マーカー：（１）ヒトＳＡＬＬ３ｃ遺伝子、（２）ヒトＥＣＥＬ１遺伝子、（３）配列番号６（NT_037622.5、1393863～1395863）とする。
PCT/JP2008/003082 2007-10-30 2008-10-29 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法 Ceased WO2009057294A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08845421.0A EP2210942B1 (en) 2007-10-30 2008-10-29 Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer
US12/740,687 US20110218121A1 (en) 2007-10-30 2008-10-29 Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer
CN200880114256A CN101855348A (zh) 2007-10-30 2008-10-29 肝癌相关基因、以及肝癌风险的判定方法
ES08845421.0T ES2510842T3 (es) 2007-10-30 2008-10-29 Gen asociado con cáncer de hígado, y método para la determinación del riesgo de adquirir cáncer de hígado

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007281552A JP5209272B2 (ja) 2007-10-30 2007-10-30 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
JP2007-281552 2007-10-30

Publications (1)

Publication Number Publication Date
WO2009057294A1 true WO2009057294A1 (ja) 2009-05-07

Family

ID=40590700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003082 Ceased WO2009057294A1 (ja) 2007-10-30 2008-10-29 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法

Country Status (6)

Country Link
US (1) US20110218121A1 (ja)
EP (1) EP2210942B1 (ja)
JP (1) JP5209272B2 (ja)
CN (1) CN101855348A (ja)
ES (1) ES2510842T3 (ja)
WO (1) WO2009057294A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103571847A (zh) * 2012-07-26 2014-02-12 汕头大学·香港中文大学联合汕头国际眼科中心 Foxc1基因突变体及其应用
CN110964822A (zh) * 2019-12-19 2020-04-07 人和未来生物科技（长沙）有限公司 一种肝癌筛查试剂盒及其使用方法与应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002345A1 (ja) * 2010-06-29 2012-01-05 エーディア株式会社 Ｐｉｖｋａ－iiの測定方法、ｐｉｖｋａ－iiの測定試薬及び抗体
US8846316B2 (en) * 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
JP6369857B2 (ja) * 2013-05-29 2018-08-08 シスメックス株式会社 肝細胞癌に関する情報の取得方法、ならびに肝細胞癌に関する情報を取得するためのマーカーおよびキット
US11484258B2 (en) * 2016-06-13 2022-11-01 Kyushu University, National University Corporation Free radical consumption speed information acquisition method and NASH determination method
CN106834528B (zh) * 2017-04-01 2019-10-29 台州市立医院 一种用于肝癌诊疗的生物标志物
CN106947830B (zh) * 2017-05-16 2019-10-08 中山大学附属肿瘤医院 用于诊断、预测肝癌疗效和预后的基因甲基化面板
CN108220421B (zh) * 2018-01-05 2019-04-05 智海基因科技南京有限公司 自身免疫性肝炎的诊断试剂盒及相关基因在制备该试剂盒中的应用
EP4549942A1 (en) * 2022-07-01 2025-05-07 Osaka University Method for checking possibility of liver cancer onset

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007192557A (ja) 2006-01-17 2007-08-02 Perseus Proteomics Inc Ｃ型肝炎患者の肝疾患の重篤化をモニターする方法および肝癌の診断方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034879A2 (en) * 2004-09-30 2006-04-06 Epigenomics Ag Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
US20090005268A1 (en) * 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007192557A (ja) 2006-01-17 2007-08-02 Perseus Proteomics Inc Ｃ型肝炎患者の肝疾患の重篤化をモニターする方法および肝癌の診断方法

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
AN BYONGGU ET AL.: "Genomewide DNA methylation analyses in cancerous and adjacent tissues from hepatocellular carcinoma patients.", THE 66TH JAPANESE CANCER ASSOCIATION GAKUJUTSU SOKAI KIJI, August 2007 (2007-08-01), pages 267 - O.271, XP008142231 *
CLARK S J ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 2990
DATABASE NCBI 29 August 2006 (2006-08-29), "Homo sapiens chromosome 2 genomic contig, reference assembly.", XP008138591, Database accession no. NT_022135 *
DATABASE NUCLEOTIDE [online] NCBI; 28 July 2007 (2007-07-28), "Homo sapiens sal-like 3 (Drosophila) (SALL3), mRNA.", XP008138294, Database accession no. NM_171999 *
DATABASE NUCLEOTIDE NCBI; 22 September 2007 (2007-09-22), "Homo sapiens endothelin converting enzyme-like 1 (ECEL1), mRNA.", XP008138296, Database accession no. NM 004826 *
DATABASE NUCLEOTIDE NCBI; 25 September 2007 (2007-09-25), "Homo sapiens forkhead box C1 (FOXC1), mRNA.", XP008138299, Database accession no. NM_001453 *
DATABASE NUCLEOTIDE NCBI; 26 September 2007 (2007-09-26), "Homo sapiens neuregulin 3 (NRG3), mRNA.", XP008138595, Database accession no. NM_001010848 *
DATABASE NUCLEOTIDE NCBI; 29 August 2006 (2006-08-29), "Homo sapiens chromosome 4 genomic contig, reference assembly.", XP008138596, Database accession no. NT_037622 *
DATABASE NUCLEOTIDE NCBI; 3 September 2007 (2007-09-03), "Homo sapiens Kv channel interacting protein 2 (KCNIP2), transcript variant 1, mRNA.", XP008138298, Database accession no. NM_014591 *
FROMMER M ET AL., PROC. NATL. ACAD. SCI. USA, 1992, pages 891827 - 1831
HIROHASHI S.: "Hito Tadankai Hatsugan Katei ni Okeru Idenshi Ijo no Haaku ni Motozuita Gan no Hontai Kaimei to Sono Rinsho Oyo ni Kansuru Kenkyu", HEISEI 16 NENDO - 18 NENDO SOGO KENKYU HOKOKUSHO, March 2007 (2007-03-01), pages 1 - 15, XP008138500 *
NAGAE G. ET AL.: "Comprehensive DNA methylation analysis in liver cancer using high-resolution tiling array.", THE 66TH JAPANESE CANCER ASSOCIATION GAKUJUTSU SOKAI KIJI, August 2007 (2007-08-01), pages 312 - 623, XP008142230 *
NT_005011 NT_005058 NT_005060 NT_005079 NT_005112 NT_005138 NT_005445 NT_019306 NT_022176 NT_022199 NT_022222 NT_026982 NT_028085 NT_029250 NT_029923 NT_030592 NT_030595 NT_031759 NT_031762 NT_032990 NT_037534 NT_077999 *
NT_006111 *
See also references of EP2210942A4 *
WONG IHN ET AL.: "Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients", CANCER RES., vol. 59, 1999, pages 71 - 73
XM_166086 *
ZHAO C. ET AL.: "Detection of aberrantly methylated genes in hepatocellular carcinoma by BAC-array based MCA(BAMCA) strategy.", THE 66TH JAPANESE CANCER ASSOCIATION GAKUJUTSU SOKAI KIJI, August 2007 (2007-08-01), pages 478 - 1025, XP008142228 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103571847A (zh) * 2012-07-26 2014-02-12 汕头大学·香港中文大学联合汕头国际眼科中心 Foxc1基因突变体及其应用
CN103571847B (zh) * 2012-07-26 2017-08-25 汕头大学·香港中文大学联合汕头国际眼科中心 Foxc1基因突变体及其应用
CN110964822A (zh) * 2019-12-19 2020-04-07 人和未来生物科技（长沙）有限公司 一种肝癌筛查试剂盒及其使用方法与应用

Also Published As

Publication number Publication date
EP2210942A1 (en) 2010-07-28
EP2210942B1 (en) 2014-08-27
JP2009106191A (ja) 2009-05-21
CN101855348A (zh) 2010-10-06
JP5209272B2 (ja) 2013-06-12
ES2510842T3 (es) 2014-10-21
US20110218121A1 (en) 2011-09-08
EP2210942A4 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
WO2009057294A1 (ja) 肝臓癌関連遺伝子、及び肝臓癌リスクの判定方法
WO2008038000A8 (en) Diagnostic method for detecting or monitoring cancer
WO2000040749A3 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
EP2138848A4 (en) METHOD FOR THE DIAGNOSIS AND / OR FORECAST OF BUBBLE CANCER
WO2008134596A3 (en) Use of methylated or unmethylated line-i dna as a cancer marker
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CN104818318A (zh) 一次性检测肺癌多重基因的引物、探针、检测体系和试剂盒
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005067391A3 (en) Diagnostic test for parkinson's disease
WO2007118704A3 (en) Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2012027483A3 (en) Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood
CN103898211A (zh) 肌萎缩侧索硬化症的基因诊断试剂盒
CN105296650B (zh) 一种检测rs9263726等位基因的探针和引物组合物
WO2008116178A8 (en) Systems and methods for diagnosis and prognosis of colorectal cancer
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2008067806A3 (de) Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin
WO2006034879A3 (en) Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2009065511A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
WO2009087689A3 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
CN104293932A (zh) 一种基于实时荧光pcr检测hla-b*5801等位基因的方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114256.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845421

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008845421

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12740687

Country of ref document: US